Put Options

4 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$12.35 - $26.11 $142,025 - $300,265
-11,500 Reduced 26.38%
32,100 $396,000
Q1 2024

May 15, 2024

SELL
$18.44 - $26.41 $295,040 - $422,560
-16,000 Reduced 26.85%
43,600 $884,000
Q4 2023

Feb 14, 2024

BUY
$12.64 - $30.11 $50,560 - $120,440
4,000 Added 7.19%
59,600 $1.34 Million
Q3 2023

Nov 15, 2023

BUY
$16.64 - $25.32 $925,184 - $1.41 Million
55,600 New
55,600 $925,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.14B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.